Medtronic tops Q3 revenue and EPS estimates as Cardiovascular and Diabetes drive growth, but margin contraction tempers the upbeat quarter.
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended January 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic (NYSE: MDT) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026.
Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $1.39 per share a year ago.
Medtronic said profit fell in its fiscal third quarter as costs rose and the company invested more money into the business, offsetting higher revenue.
Medtronic surpassed Wall Street expectations for third-quarter profit on Tuesday, buoyed by strong demand for its heart devices and diabetes monitors.
Medtronic delivered solid Q2 results with beats on revenue and EPS, but now trades at a 5% premium to fair value. Segment growth was led by Cardiovascular and Diabetes, though headwinds from Chinese procurement, tariffs, and regulatory risks persist. FY26 guidance was modestly raised, but forward EPS growth is just 2.5% and revenue guidance remains below consensus.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Medtronic (MDT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended January 2026.
Medtronic (MDT) concluded the recent trading session at $101.72, signifying a -1.15% move from its prior day's close.
Medtronic said on Tuesday it would buy privately held CathWorks in a deal valued at up to $585 million, as it looks to bolster its heart devices portfolio by adding a new diagnostic tool that could improve care standards.
In the closing of the recent trading day, Medtronic (MDT) stood at $102.96, denoting a +1.94% move from the preceding trading day.
Medtronic is divesting a business that's slowing down its margins. The company entered an important market last year.